Date: 2017-06-01
Type of information: Financing round
Company: Flashcell (France)
Investors: Auriga Partners (France) Vectalys (France)
Amount: € 1.5 million
Funding type: financing round
Planned used:
- FlashCell is a new gene therapy company specialized in the development of RNA carriers for therapeutic applications. The company will conduct proprietary therapeutic programs, but also co-development and licensing agreements with pharmaceutical or biotechnological companies for the utilization, further development and global commercialization of the LentiFlash™ non-integrative RNA delivery system.
- This technology is a class of RNA carriers based on a chimeric lentiviral platform including the MS2 bacteriophage packaging system. It has been specifically designed to package genetic materials for a transient expression of genome
editing machineries, antigens or cell specific factors in cells and tissues.
- In the following months, FlashCell will put in place the necessary resources and the structures to ensure its developments, which include:
- Building the executive, business development & scientific FlashCell ‘s teams, as well as setting up the corporate governance structures. Pascale Bouillé, CEO of Vectalys, will
also act as FlashCell’s CEO in this period of time
- Reaching preclinical proof of concept stages for the gene editing and immunotherapy programs which we are currently developing with academic teams. FlashCell will have
a privileged access to Vectalys research and future GMP lentiviral production platform to conduct these programs. The goal is to complete the preclinical development of the proprietary therapeutic program in 2018 and to start the first-in-man clinical trial in 2020.
- Implementing revenue-generating collaborative research and licensing partnerships with large biotechnology and pharmaceutical companies,
Others:
- • On June 1, 2017, Auriga Partners, an independent venture capital firm, and Vectalys, a biotech company specialized in the manufacturing of lentiviral solutions, announced the creation of FlashCell, a new gene therapy company specialized in the development of RNA carriers (non-integrating lentiviral vectors) for therapeutic applications. FlashCell will take advantage of Vectalys expertise and state of the art technology for lentiviral tools production to develop gene editing as well as immunotherapy programs for therapeutic purposes.
- FlashCell has successfully raised in a first round € 1.5 million of capital to fund its creation and the first steps of its development. AURIGA Partners, through its seed Fund AURIGA IV Bioseeds, has conducted this first private placement.
Therapeutic area:
Is general: Yes
